Oxybutynin (Ditropan): Uses, Warnings, and Side Effects

What is oxybutynin?

Oxybutynin is an antispasmodic, antimuscarinic medicine. It blocks the muscarinic action of acetylcholine and relaxes bladder smooth muscle. This can increase bladder capacity and reduce urgency, involuntary bladder contractions, and episodes of urge incontinence.

Ditropan and Ditropan XL are brand names associated with immediate-release and extended-release oxybutynin. Oxytrol is a transdermal oxybutynin system. Availability and approved instructions can differ by product and country, so check the exact label you receive.

What is oxybutynin used for?

Current U.S. prescribing information for extended-release oxybutynin lists treatment of overactive bladder with:

• urge urinary incontinence;
• urinary urgency;
• urinary frequency.

Extended-release tablets are also indicated for certain children aged 6 years and older with detrusor overactivity associated with a neurological condition, such as spina bifida. Immediate-release labeling describes use for bladder instability associated with uninhibited neurogenic or reflex neurogenic bladder.

If urinary terminology is unfamiliar, see our guide to the medical meaning of micturition. Oxybutynin is not the only medicine used for overactive bladder; vibegron works differently and has its own benefits, risks, and prescribing criteria.

Forms and typical dosing

The correct dose depends on the formulation, age, response, other health conditions, and prescriber instructions. The examples below summarize the cited U.S. labels and are not personal dosing advice.

Who should not use oxybutynin?

U.S. labeling lists these main contraindications:

• urinary retention;
• gastric retention or other severe reduction in gastrointestinal motility;
• uncontrolled narrow-angle glaucoma;
• a known serious hypersensitivity reaction to oxybutynin or a product component.

The exact contraindications can vary by formulation. A clinician should check the label for the specific product before treatment.

Warnings and precautions

Urinary and gastrointestinal retention

Oxybutynin can worsen urinary retention in people with significant bladder outflow obstruction. It can also reduce gastrointestinal motility, so caution is required with obstructive gastrointestinal disorders, intestinal atony, ulcerative colitis, gastroesophageal reflux, and medicines such as bisphosphonates that may worsen esophagitis.

Effects on the brain and alertness

Anticholinergic central nervous system effects can include drowsiness, dizziness, confusion, agitation, hallucinations, and memory impairment. Monitoring is especially important after starting treatment or increasing the dose. Do not drive or operate machinery until you know how the medicine affects you. Alcohol may increase drowsiness.

Angioedema and allergic reactions

Swelling of the face, lips, tongue, or throat has been reported and can obstruct the airway. Stop the medicine and seek emergency help for swelling of the tongue or throat, trouble breathing, or another severe allergic reaction.

Heat, sweating, and dry mouth

Anticholinergic medicines can reduce sweating and increase the risk of heat prostration in high temperatures. Reduced saliva may contribute to dental caries, gum problems, or oral candidiasis during long-term treatment.

Other conditions that need review

Tell the prescriber about dementia, Parkinson’s disease, myasthenia gravis, autonomic neuropathy, kidney or liver impairment, glaucoma, bladder obstruction, or significant gastrointestinal disease. Extended-release labeling notes that studies have not been conducted in people with renal or hepatic impairment.

Side effects

Common reactions with extended-release tablets include:

• dry mouth;
• constipation or diarrhea;
• headache;
• drowsiness;
• dizziness.

Blurred vision, dry eyes, nausea, difficulty urinating, and urinary retention can also occur. With the Oxytrol patch, application-site itching, redness, rash, or small blisters are among the most common reactions.

Contact a healthcare professional promptly if side effects are severe, persistent, or include inability to urinate, marked confusion, eye pain with vision changes, or a serious skin reaction. Seek emergency help for breathing difficulty or swelling of the face, tongue, or throat.

Drug interactions

Oxybutynin can have additive effects with other anticholinergic medicines or other drugs that cause dry mouth, constipation, drowsiness, or blurred vision. It may oppose the effects of prokinetic medicines such as metoclopramide and can change absorption of some medicines by slowing gastrointestinal motility.

Strong CYP3A4 inhibitors can increase oxybutynin exposure. U.S. labeling specifically discusses ketoconazole and advises caution with other CYP3A4 inhibitors, including itraconazole, miconazole, erythromycin, and clarithromycin. For background on one of these medicines, see our ketoconazole guide. A pharmacist should review the complete medicine and supplement list before oxybutynin is started.

Pregnancy and breastfeeding

Current extended-release labeling states that there are no adequate data in pregnant women to evaluate the risk of major birth defects, miscarriage, or adverse maternal or fetal outcomes. It also states that there are no data on oxybutynin in human milk, its effects on a breastfed child, or its effects on milk production.

During pregnancy or breastfeeding, the decision should be individualized with a healthcare professional by weighing the clinical need, expected benefits, and possible risks.

Use in children and older adults

Age limits and approved uses depend on the formulation. Extended-release tablets have a specific indication for children aged 6 years and older with detrusor overactivity associated with a neurological condition and are not recommended for children who cannot swallow the tablet whole. Immediate-release labeling includes dosing for children over 5 years with its labeled indication.

Older adults may be more vulnerable to anticholinergic effects such as confusion, constipation, urinary retention, blurred vision, and falls. Individual review is important, especially when several medicines with anticholinergic effects are used together.

Frequently asked questions

Is oxybutynin the same as Ditropan?

Oxybutynin is the active ingredient. Ditropan and Ditropan XL are brand names associated with immediate-release and extended-release formulations.

Can an extended-release tablet be split?

No. The cited extended-release label says to swallow the tablet whole and not chew, divide, or crush it.

How often is the Oxytrol patch changed?

The cited prescription label says twice weekly, every 3 to 4 days. Use a new application site and do not return to the same site within 7 days.

What are the most common side effects?

Dry mouth, constipation, diarrhea, headache, drowsiness, and dizziness are among the most common reactions listed for extended-release tablets. Patch products commonly cause application-site reactions and dry mouth.

When should urgent help be sought?

Seek urgent medical help for trouble breathing, swelling of the tongue or throat, inability to urinate, severe confusion, or severe eye pain with visual changes.

Official sources

• DailyMed: oxybutynin chloride immediate-release tablets — U.S. prescription label, updated January 4, 2023.
• DailyMed: oxybutynin chloride extended-release tablets — current listing reviewed, updated December 24, 2025.
• DailyMed: Oxytrol prescription transdermal system — U.S. label revised May 2024.